In myeloma treatment, acute CRS is a common but treatable AE associated with CAR T-cell therapy and bispecific antibodies, ...
Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...
Siltuximab effectively treated patients who experienced common adverse events after chimeric antigen receptor T-cell therapy, ...
Oncologists are increasingly favoring CAR T-cell therapy’s early-line use in relapsed/refractory multiple myeloma despite ...
Zacks Small Cap Research on MSN5d
INAB: Introducing INB-600, A γδ T Cell Engager PlatformINAB READ THE FULL INAB RESEARCH REPORT Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc ...
The data from the Phase 1/1b clinical trial of soquelitinib in patients with T cell lymphoma continues to demonstrate strong indications of anti-tumor activity in a significant number of patients,” ...
Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. | Immunocore’s big swing for a functional HIV ...
The Lupus Research Alliance (LRA) is proud to announce the inaugural recipients of the new Targeted Research Program on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback